Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $3.1 million.

  • Pharma's Cash from Financing Activities rose 29168.77% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 2883.79%. This contributed to the annual value of $4.5 million for FY2025, which is 2630.53% up from last year.
  • According to the latest figures from Q3 2025, Pharma's Cash from Financing Activities is $3.1 million, which was up 29168.77% from $851000.0 recorded in Q2 2025.
  • In the past 5 years, Pharma's Cash from Financing Activities ranged from a high of $14.2 million in Q1 2021 and a low of -$1000.0 during Q4 2021
  • Its 5-year average for Cash from Financing Activities is $1.7 million, with a median of $696500.0 in 2021.
  • In the last 5 years, Pharma's Cash from Financing Activities tumbled by 10013.77% in 2022 and then soared by 25080000.0% in 2024.
  • Over the past 5 years, Pharma's Cash from Financing Activities (Quarter) stood at -$1000.0 in 2021, then skyrocketed by 10300.0% to $102000.0 in 2022, then tumbled by 100.98% to -$1000.0 in 2023, then soared by 34600.0% to $345000.0 in 2024, then surged by 801.45% to $3.1 million in 2025.
  • Its Cash from Financing Activities stands at $3.1 million for Q3 2025, versus $851000.0 for Q2 2025 and $805000.0 for Q1 2025.